cas 10386-27-3|| where to buy 2-Bromo-4-cyanopyridine

Nom du produit:2-Bromo-4-cyanopyridine

IUPAC Name:2-bromopyridine-4-carbonitrile

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM120633-100g	in stock	șƏǕ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 10386-27-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:10386-27-3; Formule moléculaire:C6H3BrN2; Point de fusion:-; Code SMILES:N#CC1=CC(Br)=NC=C1; Densité:

: Numéro de catalogue:CM120633; Poids moléculaire:183.01; Point d'ébullition:; N° Mdl:MFCD07367879; Stockage:

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Ivosidenib; Tibsovo (ivosidenib tablets) is a precision medicine that targets a specific type of mutation known as isocitrate dehydrogenase 1 (IDH1). Tibsovo is approved in five indications globally, including approvals in the U.S., European Union, Australia, and China.
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation.
Fifth approved indication for Tibsovo solidifies Servier’s leadership in mutant IDH inhibition.